Serum Hyaluronan as a Disease Marker

Laurent, Torvard C.; Laurent, Ulla B.G.; Fraser, J. R. E.

doi:10.3109/07853899609033126

Cited by 167 publications

(131 citation statements)

References 119 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Many other studies, see [5], have confirmed these findings; the mean values of the circulating HYA in these studies vary between 71 and 297 g L compared with 17-54 g L in controls. The finding is also confirmed in studies on animals with experimental arthritis [8].…”

Section: Serum Analysis In Rheumatic Diseasessupporting

confidence: 58%

See 1 more Smart Citation

Hyaluronan in joint disease

Engström‐Laurent

1997

Journal of Internal Medicine

View full text Add to dashboard Cite

Engström‐Laurent A (University of Umeå, Umeå, Sweden). Hyaluronan in joint disease (Minisymposium: Hyaluronan). J Intern Med 1997; 242: 57–60. Hyaluronan is a major component of synovial fluid. It is synthesized in the joint and partly degraded in joint capsule and partly carried by lymph to lymph nodes and the general circulation. During various joint disorders, especially inflammatory ones, the amount of hyaluronan in the joint and its turnover rate are increased leading to pathologically high serum levels of the polysaccharide. These levels are a complex function of synovitis mass and the physical activity of the patient. Intra‐articular injection of hyaluronan has been used in the treatment of osteoarthritis. Although it results in a relief of pain, controlled clinical trials have not yet convincingly shown any beneficiary effects of the treatment.

show abstract

Section: Serum Analysis In Rheumatic Diseasessupporting

confidence: 58%

“…A large clinical material has therefore been accumulated [5]. Many other components can also be analysed today through the development of sensitive assays of different types, e.g.…”

Section: Introductionmentioning

confidence: 99%

Hyaluronan in joint disease

Engström‐Laurent

1997

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Serum levels in middle-aged individuals range from 10-100 ng/mL (2). Although serum hyaluronan levels are known to be increased in several conditions, such as liver disease or inflammatory disease, and they can be as high as 2,000 ng/mL (2). We measured the serum hyaluronan levels in one patient with collagenofibrotic glomerulopathy and found that they were >100,000 ng/mL, although other symptoms of liver disease and inflammation were absent.…”

Section: Introductionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Marked Elevation of Serum Hyaluronan Levels in Collagenofibrotic Glomerulopathy

et al. 2014

View full text Add to dashboard Cite

Collagenofibrotic glomerulopathy is a rare glomerular disease characterized by the massive deposition of type III collagen in mesangial and subendothelial spaces. We observed markedly increased serum hyaluronan levels in patients with collagenofibrotic glomerulopathy; levels in three patients were more than 1,000-times greater than the normal upper limit. However, one kidney transplant patient had normal serum hyaluronan levels. We found that serum levels and activities of the enzyme hyaluronidase were normal, and hyaluronan was not markedly deposited in the mesangial or subendothelial spaces. Our findings suggest that serum hyaluronan levels may be a specific diagnostic marker of collagenofibrotic glomerulopathy, and kidney transplantation may alleviate marked increases in serum hyaluronan.

show abstract

“…8,9 HA is synthesized throughout the body in mesenchymal cells and translocated into the extracellular spaces. 8,9 Prostaglandin E2, fibroblast growth factor, and transforming growth factor-␤ have been shown to stimulate the synthesis of HA. 10 Hyaluronic acid is cleared, almost exclusively, by hepatic sinusoidal endothelial cells (SEC).…”

mentioning

confidence: 99%

Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation

Fried

Duncan

Soroka

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The development of hepatic veno-occlusive disease following bone marrow transplantation is associated with high-dose combination cytoreductive therapy. Experimental models have suggested that drug-induced injury to hepatic sinusoidal endothelial cells is involved in the pathogenesis of this syndrome. Hyaluronic acid is a polysaccharide that is metabolized, almost exclusively, by hepatic sinusoidal endothelial cells. The aim of the present study was to evaluate serum hyaluronic acid as a marker for endothelial cell injury in patients with veno-occlusive disease following bone marrow transplantation. Hyaluronic acid was measured in sera from patients with and without veno-occlusive disease using an enzyme-linked protein binding assay. Mean peak serum hyaluronic acid levels were significantly greater in patients who had a diagnosis of VOD compared to those transplant patients who did not, 1173.4 ± 982.9 vs 444.9 ± 735.6 ng/ml (P = 0.01). Serial serum samples obtained from a separate cohort of patients also demonstrated that serum hyaluronic acid levels were higher in patients with moderate or severe veno-occlusive disease compared to those with none or mild disease at days 7, 17 and 25 following transplantation (greatest difference at day 25: 366 ± 327 vs 126 ± 151, P = 0.01). Serum hyaluronic acid levels are increased in veno-occlusive disease and increase over time in patients with severe disease. Further studies are required to determine if elevated serum hyaluronic acid levels are due to decreased clearance by injured hepatic sinusoidal endothelial cells or increased production from early hepatic fibrogenesis associated with the acute liver injury. Hepatic veno-occlusive disease (VOD) is a life-threatening complication of bone marrow transplantation (BMT) that is defined by the appearance of jaundice, tender hepatomegaly, and ascites. 1-3 Clinical manifestations of VOD usually occur within 3 weeks of transplant and vary in their severity. Mild VOD may be self-limited and resolve with supportive care, while severe VOD causes progressive hepatic synthetic dysfunction and complications of portal hypertension that culminate in multi-organ failure and death. 2 The histologic changes of VOD occur predominantly in the centrizonal region of the hepatic lobule and are characterized by subendothelial edema, occlusion of terminal hepatic venules, hepatocyte necrosis, and sinusoidal fibrosis. 4 The incidence of VOD following transplantation ranges between 10% and 54% depending on the cytoreductive regimen and the criteria used to define the syndrome. 2,3,5 The development of VOD has been strongly associated with high-dose combination cytoreductive therapy, particularly regimens that contain cyclophosphamide coupled with total body irradiation, busulfan, carmustine, or etoposide. 2,3 Several studies have provided evidence that injury to hepatic sinusoidal endothelial cells by chemotherapeutic agents is an early event in the pathogensis of VOD. 6,7 In cell culture, isolated sinusoidal endothelial cells were more susc...

show abstract

Serum Hyaluronan as a Disease Marker

Cited by 167 publications

References 119 publications

Hyaluronan in joint disease

Hyaluronan in joint disease

Marked Elevation of Serum Hyaluronan Levels in Collagenofibrotic Glomerulopathy

Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation

Contact Info

Product

Resources

About